SCHEMBL4263131

SCHEMBL4263131

NC(=O)c1ccc(F)cc1C(F)(F)F.O=S(=O)(O)/C=C/c1cccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.47
ALDH1A1 P00352 1/20 0.46
NAMPT P43490 8/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALOX5 P09917 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
JUN P05412 1/20 0.38
MAPT P10636 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
NTSR1 P30989 1/20 0.38
HDAC3 O15379 1/20 0.37
NCOR1 O75376 1/20 0.37
HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27706035 1.00 NFE2L2 (0.47) NFE2L2ALDH1A1NAMPTMEN1KMT2A
SCHEMBL4261210 0.90 NAMPT (0.45) NFE2L2NAMPTALOX5PTGS1PTGS2
SCHEMBL4258583 0.87 NFE2L2 (0.45) NFE2L2ALDH1A1NAMPTMEN1KMT2A
SCHEMBL4620011 0.87 HTR2A (0.41) ALDH1A1MEN1KMT2APTGS2KDM4E
SCHEMBL27717789 0.87 HTR2A (0.41) ALDH1A1MEN1KMT2APTGS2KDM4E
SCHEMBL4262713 0.86 NFE2L2 (0.50) NFE2L2ALDH1A1NAMPTMEN1KMT2A
SCHEMBL27726712 0.86 NFE2L2 (0.50) NFE2L2ALDH1A1NAMPTMEN1KMT2A
SCHEMBL5408888 0.83 PTGES2 (0.46) NFE2L2MEN1KMT2ARAB9ANPC1
SCHEMBL27717776 0.83 PTGES2 (0.46) NFE2L2MEN1KMT2ARAB9ANPC1
SCHEMBL4375635 0.81 NAPRT (0.51) NFE2L2NAMPTKMT2APTGS2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
CN-101208325-A Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-06-25 CN claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
CN-101208325-A Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-06-25 CN disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 NFE2L2 270/4885ALDH1A1 148/4885NAMPT 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.